바이오라인알엑스(BLRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.76 (+1.52%), 시가총액 $0.01B, 52주 범위 $2.18 ~ $5.93.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered
바이오라인알엑스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
바이오라인알엑스의 현재 주가는 $2.76 (+1.52%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
바이오라인알엑스의 시가총액은 약 $0.01B입니다.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damag